|1.||Kakauridze, N G: 1 article (11/2014)|
|2.||Lezhava, T A: 1 article (11/2014)|
|3.||Gaiozishvili, M N: 1 article (11/2014)|
|4.||Buadze, T Zh: 1 article (11/2014)|
|5.||Dzhokhadze, T A: 1 article (11/2014)|
|6.||Lezhava, Teimuraz: 1 article (04/2007)|
|7.||Jokhadze, Tina: 1 article (04/2007)|
11/01/2014 - "The identified protective action of Livagen proves its efficacy in prevention of atherosclerosis. "
11/01/2014 - "The results show that Livagen separately and in combination with cobalt ions has impact on chromatin of patients with atherosclerosis. "
11/01/2014 - "It was also shown that Livagen (characterized by modifying influence on chromatin) separately and in combination with cobalt ions, promotes normalization of altered genomic indicators of atherosclerosis in both age groups. "
|2.||Chromosomal Instability (Chromosome Stability)
04/01/2007 - "The functional characteristics of chromosomes (level of total heterochromatin, chromosome instability, and sister chromatid exchanges [SCEs]) were studied in cultured lymphocytes derived from 80- to 91-year-old and 18- to 30-year-old (control group) individuals under the single and combined effect of CoCl(2) and bioregulator Livagen. "
|3.||Hypertrophic Cardiomyopathy (Asymmetric Septal Hypertrophy)
09/01/2014 - "The influence of peptide bioregulator - Livagen (Lys-Glu-Asp-Ala) separately and combined with cobalt ions, on the activity of nucleolar organizer regions (NORs) and frequency of associations of acrocentric chromosomes in lymphocytes from patients with hypertrophic cardiomyopathy (HCM) and their relatives has been studied. "
|6.||cobaltous chloride (cobalt(II)chloride)